Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06777602 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06777602 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants.
The verdict
NCT06777602, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Interventions
- DRUG [14C] MK-5475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-15 |
| Est. Completion | 2022-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06777602
The ClinicalTrials.gov registry entry for NCT06777602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C] MK-5475 is the first listed.
NCT06777602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06777602 about?
NCT06777602 is a clinical study titled "A Clinical Study To Understand How Radiolabeled MK-5475 Is Taken Up By The Body, Broken Down And Then Removed From The Body in Healthy Participants (MK-5475-011)". The goal of this study is to understand how radiolabeled MK-5475 administered intravenously (IV) is taken up by the body, broken down and then removed from the body in healthy male participants. The study also aims to understand how much of the compound is broken down and how much leaves the body un...
What is the current status of trial NCT06777602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-08-15. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT06777602?
The interventions under investigation include: [14C] MK-5475 (DRUG).
Who is sponsoring clinical trial NCT06777602?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.